University of California, Davis

Epidemics of recent emerging infectious diseases, such as the H1N1 pandemic, demand cost-efficient and scalable production technologies that can rapidly deliver effective therapeutics to clinics. Traditional vaccine manufacturers have trouble meeting these needs, as their manufacturing processes are slow and not economically scalable. Developing world populations are especially burdened by lack of access to large quantities of effective and inexpensive therapies.
This team is developing SwiftVax, a plant-based production platform that produces animal and human vaccines efficiently and affordably. The technology can rapidly produce large amounts of therapeutics with minimal investment compared to traditional vaccine production infrastructure.
The team’s initial target product is an animal vaccine for Newcastle Disease, a devastating and highly pathogenic disease in poultry. The disease threatens commercial poultry in developed countries as well as the livelihood of disadvantaged populations in Africa, to whom chickens represent the main source of food and income.